JP2024038034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038034A5 JP2024038034A5 JP2023216425A JP2023216425A JP2024038034A5 JP 2024038034 A5 JP2024038034 A5 JP 2024038034A5 JP 2023216425 A JP2023216425 A JP 2023216425A JP 2023216425 A JP2023216425 A JP 2023216425A JP 2024038034 A5 JP2024038034 A5 JP 2024038034A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- antigen
- binding fragment
- durvalumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| JP2019543851A JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Division JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038034A JP2024038034A (ja) | 2024-03-19 |
| JP2024038034A5 true JP2024038034A5 (https=) | 2024-05-27 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (https=) |
| EP (1) | EP3582805A4 (https=) |
| JP (2) | JP2020507596A (https=) |
| KR (3) | KR20190117014A (https=) |
| CN (2) | CN110290803A (https=) |
| AU (2) | AU2018221822A1 (https=) |
| CA (1) | CA3052652A1 (https=) |
| EA (1) | EA201991870A1 (https=) |
| IL (3) | IL302777A (https=) |
| MA (1) | MA47509A (https=) |
| SG (1) | SG11201907211TA (https=) |
| WO (1) | WO2018152415A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3142751T (pt) * | 2014-05-13 | 2019-10-25 | Medimmune Ltd | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. |
| SG11201907211TA (en) * | 2017-02-16 | 2019-09-27 | Medimmune Llc | Anti-pd-l1 antibody treatment of bladder cancer |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| EP4153783A1 (en) * | 2020-05-21 | 2023-03-29 | Astrazeneca AB | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma |
| US20250388678A1 (en) * | 2024-06-25 | 2025-12-25 | Astrazeneca Ab | Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| PT3142751T (pt) * | 2014-05-13 | 2019-10-25 | Medimmune Ltd | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. |
| NZ733854A (en) * | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| JP7144935B2 (ja) * | 2015-05-29 | 2022-09-30 | ジェネンテック， インコーポレイテッド | 癌のための治療方法及び診断方法 |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| SG11201907211TA (en) * | 2017-02-16 | 2019-09-27 | Medimmune Llc | Anti-pd-l1 antibody treatment of bladder cancer |
-
2018
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038034A5 (https=) | ||
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| Wehler et al. | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer | |
| JP2017537105A5 (https=) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| RU2012140447A (ru) | Антиангиогенная терапия для лечения рака яичника | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2020517696A5 (https=) | ||
| JP2020507596A5 (https=) | ||
| JP2019532047A5 (https=) | ||
| Wang et al. | Dihydromyricetin alleviates inflammatory bowel disease associated intestinal fibrosis by inducing autophagy through the PI3K/AKT/mTOR signaling pathway | |
| Liu et al. | Chitooligosaccharides attenuated hepatic encephalopathy in mice through stabilizing gut–liver–brain disturbance | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2008505143A5 (https=) | ||
| JP2015528802A5 (https=) | ||
| WO2020200305A1 (zh) | 一种含羟基脲的药物组合物的应用 | |
| CN104138386A (zh) | 柴胡皂苷d对肿瘤多药耐药逆转作用的医药用途 | |
| JPWO2020223702A5 (https=) | ||
| TWI798243B (zh) | 治療癌症的方法 | |
| JP2020520905A5 (https=) | ||
| JPWO2020112765A5 (https=) | ||
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 | |
| CN115515571A (zh) | 胰腺癌的治疗方法 | |
| RU2629599C1 (ru) | Способ химиолучевого лечения опухолей прямой кишки и анального канала | |
| TW201420130A (zh) | 溶解有二氧化碳之液狀藥劑及其投藥方法 |